Resmed (RMD)

Company Profile

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Company profile

Ticker

RMD, RSMDF

Exchange

NYSE

Website

www.resmed.com/

CEO

Michael Farrell

Incorporated

Delaware

Location

California

Fiscal year end

Jun 30

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton Dickinson & Co. • Teleflex • West Pharmaceutical Services • Haemonetics • Hill-Rom • Integra Lifesciences ...

SEC CIK

0000943819

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

ResMed Corp. • ResMed (UK) Ltd • ResMed Asia Pacific Ltd • ResMed Beteiligungs GmbH • ResMed Holdings Pty Ltd • ResMed Pty Ltd • ResMed GmbH and Co • ResMed Motor Technologies Inc. • ResMed SAS • ResMed Paris SAS ...

IRS number

980152841

RMD stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

10 Aug 23

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023

3 Aug 23

Conflict minerals disclosure

27 Apr 23

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023

27 Apr 23

8-K

Departure of Directors or Certain Officers

26 Jan 23

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023

26 Jan 23

8-K

Submission of Matters to a Vote of Security Holders

27 Oct 22

Transcripts

View all

RMD

Earnings call transcript

2023 Q4

3 Aug 23

RMD

Earnings call transcript

2023 Q3

27 Apr 23

RMD

Earnings call transcript

2023 Q2

26 Jan 23

RMD

Earnings call transcript

2023 Q1

28 Oct 22

RMD

Earnings call transcript

2022 Q4

12 Aug 22

RMD

Earnings call transcript

2022 Q3

29 Apr 22

RMD

Earnings call transcript

2022 Q2

28 Jan 22

RMD

Earnings call transcript

2022 Q1

29 Oct 21

RMD

Earnings call transcript

2021 Q4

6 Aug 21

RMD

Earnings call transcript

2021 Q3

30 Apr 21

Latest ownership filings

View all

Michael J. Farrell

19 Sep 23

144

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart RMD financial data

Quarter (USD)	Jun 23	Mar 23	Dec 22	Sep 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 23	Jun 22	Jun 21	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	227.89 mm	227.89 mm	227.89 mm	227.89 mm	227.89 mm	227.89 mm
Cash burn (monthly)	1.00 k	3.82 mm	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	2.88 k	11.01 mm	n/a	n/a	n/a	n/a
Cash remaining	227.89 mm	216.88 mm	n/a	n/a	n/a	n/a
Runway (months of cash)	227888.1	56.8	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Resmed earnings reports.

Institutional ownership, Q2 2023

RMD institutional ownership history Ownership history

63.6% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	698	654	+6.7%
Opened positions	93	45	+106.7%
Closed positions	49	104	-52.9%
Increased positions	244	231	+5.6%
Reduced positions	243	257	-5.4%

13F shares	Current	Prev Q	Change
Total value	20.39 tn	20.44 tn	-0.3%
Total shares	93.53 mm	93.63 mm	-0.1%
Total puts	76.30 k	56.30 k	+35.5%
Total calls	855.17 k	158.68 k	+438.9%
Total put/call ratio	0.1	0.4	-74.9%

Largest owners	Shares	Value	Change
Vanguard	17.58 mm	$3.84 tn	+0.3%
BLK Blackrock	12.24 mm	$2.67 tn	-6.9%
STT State Street	6.39 mm	$1.40 tn	+1.6%
FMR	6.09 mm	$1.33 tn	-6.2%
WCM Investment Management	3.50 mm	$768.72 bn	+0.7%
Geode Capital Management	3.33 mm	$725.60 bn	+3.0%
Capital World Investors	2.36 mm	$515.03 bn	-44.5%
IVZ Invesco	2.10 mm	$459.05 bn	+8.1%
Citadel Advisors	1.86 mm	$406.21 bn	-11.6%
NTRS Northern Trust	1.62 mm	$353.04 bn	-7.6%

Largest transactions	Shares	Bought/sold	Change
Capital World Investors	2.36 mm	-1.89 mm	-44.5%
BLK Blackrock	12.24 mm	-900.87 k	-6.9%
Millennium Management	632.02 k	+632.02 k	NEW
MNGPF Man	477.02 k	+477.02 k	NEW
Assenagon Asset Management	526.20 k	+410.82 k	+356.1%
FMR	6.09 mm	-404.51 k	-6.2%
Amundi	683.40 k	-321.96 k	-32.0%
Jane Street	376.94 k	+309.37 k	+457.9%
Qube Research & Technologies	377.90 k	+288.39 k	+322.2%
Renaissance Technologies	390.70 k	+261.50 k	+202.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RMD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Sep 23	Farrell Michael J.	ResMed Common Stock	Sell	Dispose S	No	Yes	146.346	5,675	830.51 k	449,360
15 Sep 23	Farrell Michael J.	ResMed Common Stock	Option exercise	Acquire M	No	Yes	57.76	5,675	327.79 k	455,035
15 Sep 23	Farrell Michael J.	ResMed Common Stock Options ResMed Common Stock	Option exercise	Dispose M	No	Yes	57.76	5,675	327.79 k	14,815
1 Sep 23	Michael J Rider	ResMed Common Stock	Sell	Dispose S	No	Yes	161.15	25	4.03 k	7,408
25 Aug 23	Lucile Blaise	ResMed Common Stock	Payment of exercise	Dispose F	No	No	165.67	379.689	62.90 k	10,355
17 Aug 23	Farrell Michael J.	ResMed Common Stock	Grant	Acquire A	No	No	0	12,430	0.00	449,360
17 Aug 23	Sandercock Brett	ResMed Common Stock	Grant	Acquire A	No	No	0	4,972	0.00	95,915